SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
BenzingaSep 13 12:17 ET
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
BenzingaSep 13 12:00 ET
Natera Analyst Ratings
BenzingaSep 13 11:26 ET · Ratings
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Seeking AlphaSep 13 11:20 ET
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
BenzingaSep 13 07:06 ET
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
cls.cnSep 12 18:22 ET

Comments

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

+1

CPI hits 3-year low: How will it sway the Fed rate decision?

15

3

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

5

1

DDDDDDDDDDD

Aug 19 11:35

$SPDR S&P Biotech ETF (XBI.US)$ EASY TO SHORT $Sunshine Biopharma (SBFM.US)$ in the RAIN

Meltyy

Aug 6 02:51

$XBI down 3% today and 5% since before last Friday’s jobs report.

$SPDR S&P Biotech ETF (XBI.US)$
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...

1

XBI SPDR S&P Biotech ETF

Trade Overview

Capital Trend

News

Comments